Advertisement
Australia markets open in 35 minutes

  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     

  • AUD/USD

    0.6700
    +0.0005 (+0.07%)
     

  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     

  • OIL

    79.87
    -0.19 (-0.24%)
     

  • GOLD

    2,423.70
    +6.30 (+0.26%)
     

  • Bitcoin AUD

    98,894.30
    -1,112.52 (-1.11%)
     

  • CMC Crypto 200

    1,354.42
    -19.42 (-1.41%)
     

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

Business Wire
·1-min read

WALTHAM, Mass., November 16, 2023--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter/X or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116711808/en/

Contacts

Media and Investor:
ir@allovir.com